Gemcitabine_hydrochloride
Category
Gemcitabine_hydrochloride Brand names, Gemcitabine_hydrochloride Analogs
Gemcitabine_hydrochloride Brand Names Mixture
No information avaliable
Gemcitabine_hydrochloride Chemical_Formula
C9H11F2N3O4
Gemcitabine_hydrochloride RX_link
http://www.rxlist.com/cgi/generic/gemcitab.htm
Gemcitabine_hydrochloride fda sheet
Gemcitabine_hydrochloride msds (material safety sheet)
Gemcitabine_hydrochloride Synthesis Reference
No information avaliable
Gemcitabine_hydrochloride Molecular Weight
263.198 g/mol
Gemcitabine_hydrochloride Melting Point
168.64oC
Gemcitabine_hydrochloride H2O Solubility
Soluble
Gemcitabine_hydrochloride State
Solid
Gemcitabine_hydrochloride LogP
-1.318
Gemcitabine_hydrochloride Dosage Forms
Lyophilized powder for injection
Gemcitabine_hydrochloride Indication
For the first-line treatment of patients with metastatic breast cancer, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer and as first-line treatment for patients with adenocarcinoma of the pancreas.
Gemcitabine_hydrochloride Pharmacology
Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand.
Gemcitabine_hydrochloride Absorption
100%
Gemcitabine_hydrochloride Toxicity
Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD50=500 mg/kg (orally in mice and rats)
Gemcitabine_hydrochloride Patient Information
General ¡ª Patients receiving therapy with Gemzar should be monitored closely by a physician
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.
Laboratory Tests ¡ª Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.
Gemcitabine_hydrochloride Organisms Affected
Humans and other mammals
